Physician profile
Peter M Eyvazzadeh
NPI 1356752810
$18,722.44
in general payments reported to CMS, 2019-2025
18 companies · $323 in 2025
The $323 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,224 · 2020: $2,630 · 2021: $9,901 · 2022: $3,270 · 2023: $185 · 2024: $190 · 2025: $323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $698.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $697.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kairos Surgical INC | $9,325.65 | 2020-2023 | |
| Arthrex, INC. | $4,021.64 | 2020-2022 | |
| Smith+Nephew, INC. | $2,332.58 | 2020-2025 | Pico, Pico 7, Acticoat 4" X 4" |
| Liberty Surgical INC. | $1,104.00 | 2019 | |
| Medical Device Business Services, INC. | $934.74 | 2019 | |
| Zimmer Biomet Holdings, INC. | $211.53 | 2019-2025 | Juggerknotless Soft Anchor, Gel-One Cross-Linked Hyaluronate |
| Ferring Pharmaceuticals INC. | $134.46 | 2021-2024 | Euflexxa |
| Pacira Pharmaceuticals Incorporated | $119.16 | 2021-2024 | Iovera, Zilretta, Exparel |
| Endo USA, INC. | $106.16 | 2024-2025 | Xiaflex |
| Stryker Corporation | $95.47 | 2020-2025 | Mako |
| Alexion Pharmaceuticals, INC. | $89.48 | 2021 | |
| Innovation Technologies INC | $69.63 | 2025 | Irrisept |
| Boston Scientific Corporation | $49.84 | 2025 | Artisan |
| Supreme Orthopedic Systems, LLC | $35.62 | 2019 | |
| Orthofix Medical, INC. | $29.96 | 2021-2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioventus LLC | $25.91 | 2023 | Durolane |
| Vertex Pharmaceuticals Incorporated | $19.82 | 2025 | |
| Fidia Pharma USA INC. | $16.79 | 2025 | Hymovis, Triluron |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Eyvazzadeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.